BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, November 29, 2024
Breaking News: Healing a health divide (that’s long overdue)
See today's BioWorld Science
Home
» Novel conjugated AAV candidate for the treatment of PD with GBA1 mutations
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Neurology/Psychiatric
Novel conjugated AAV candidate for the treatment of PD with GBA1 mutations
Oct. 31, 2023
No Comments
Researchers from Coave Therapeutics SA presented a novel conjugated AAV (coAAV)-GBA1 candidate for the treatment of patients suffering from PD related to GBA1 mutations.
BioWorld Science
Conferences
Gene therapy
Genetic/congenital
Neurology/psychiatric
